Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - benzatropine mesilate, quantity: 1 mg/ml - injection - excipient ingredients: sodium chloride; water for injections - benzatropine injection is recommended for all forms of parkinsonism - including arteriosclerotic, post-encephalitic, idiopathic, as well as drug induced extrapyramidal disorders (except tardive dyskinesia). it can be effective at any stage of the disease, even when a patient has become bedridden. benzatropine injection often is helpful in patients who have become unresponsive to other agents. benzatropine injection is a powerful antichlolinergic agent which is mainly effective in relieving tremor and rigidity. therapy is directed toward control of disturbing symptoms to permit the patient maximum integration of function with minimum discomfort. in non-drug-induced parkinsonism, partial control of symptoms is usually achieved.

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratoire aguettant - atropine sulfate monohydrate - solution for injection in pre-filled syringe - 0.1 milligram(s)/millilitre - belladonna alkaloids, tertiary amines; atropine - belladonna alkaloids, tertiary amines - atropine sulfate aguettant 0.1 mg/ml, solution for injection in pre-filled syringe is indicated in adults and in paediatric population from birth, but with a body weight superior to 3 kg - as a pre-anaesthetic medication to prevent vagal reactions associated with tracheal intubation and surgical manipulation, - to limit the muscarinic effects of neostigmine, when given postsurgically to counteract non-depolarising muscle relaxants - treatment of hemodynamically compromising bradycardia and/ or atrioventricular block due to excessive vagal tone in emergency situation - cardiopulmonary resuscitation: to treat symptomatic bradycardia and av block - as antidote following overdosage or poisoning with acetylcholinesterase-inhibitors e.g. anticholinesterases, organophosphorus, carbamates and muscarinic mushrooms

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoire aguettant - atropine sulfate 0,1 mg/ml - eq. atropine 0,083 mg/ml - solution for injection in pre-filled syringe - 0,1 mg/ml - atropine sulfate 0.1 mg/ml - atropine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - atropine sulfate monohydrate 0,1 mg/ml - eq. atropine 0,083 mg/ml - solution for injection in pre-filled syringe - 0,1 mg/ml - atropine sulfate monohydrate 0.1 mg/ml - atropine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - atropine sulfate monohydrate 0,1 mg/ml - eq. atropine 0,083 mg/ml - solution for injection in pre-filled syringe - 0,1 mg/ml - atropine sulfate monohydrate 0.1 mg/ml - atropine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

noridem enterprises ltd. - atropine sulfate 1 mg/ml - solution for injection - 1 mg/ml - atropine sulfate 1 mg/ml - atropine

Kenya - English - Pharmacy and Poisons Board

medisel kenya ltd p.o box 540-01000 thika - atropine 1mg/ml - injection - atropine 1mg/ml - plain belladonna and derivatives: belladonna

Kenya - English - Pharmacy and Poisons Board

atropine injection 1mg/ml 1ml ampoule - injection - 1mg/ml - atropine

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - somatropin, quantity: 10 mg/ml - injection, solution - excipient ingredients: histidine; phenol; poloxamer; mannitol; water for injections - children:treatment of growth failure in children due to pituitary growth hormone deficiency. treatment of growth failure in girls due to gonadal dysgenesis (turner's syndrome). treatment of growth failure in children due to chronic renal insufficiency whose height is on or less than the twenty-fifth percentile and whose growth velocity is on or less than the twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 30 ml/min/1.73 m2. treatment of severe growth failure due to intrauterine growth retardation (i.e., children born small for gestational age (birth weight and/or length < -2 sd) without spontaneous catch up growth by 2 years of age). adults: treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. in order to establish childhood onset [co] growth hormone insufficiency, reconfirmation by

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - somatropin, quantity: 6.67 mg/ml - injection, solution - excipient ingredients: poloxamer; mannitol; histidine; water for injections; phenol - children:treatment of growth failure in children due to pituitary growth hormone deficiency. treatment of growth failure in girls due to gonadal dysgenesis (turner's syndrome). treatment of growth failure in children due to chronic renal insufficiency whose height is on or less than the twenty-fifth percentile and whose growth velocity is on or less than the twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 30 ml/min/1.73 m2. treatment of severe growth failure due to intrauterine growth retardation (i.e., children born small for gestational age (birth weight and/or length < -2 sd) without spontaneous catch up growth by 2 years of age). adults: treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. in order to establish childhood onset [co] growth hormone insufficiency, reconfirmation by